BioCentury

7:00 AM GMT, Sep 6, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Lovenox enoxaparin: Phase III data

In the open-label, international Phase III ATOLL trial in 910 patients, 0.5 mg/kg IV Lovenox administered prior

Read the full 170 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.